Neurosurgical Department, Bagdasar-Arseni Clinical Emergency Hospital, 041915 Bucharest, Romania.
Neurosurgical Department, Carol Davila University of Medicine and Pharmacy, 020022 Bucharest, Romania.
Int J Mol Sci. 2024 Oct 7;25(19):10765. doi: 10.3390/ijms251910765.
Glioblastoma is known to be one of the most aggressive and fatal human cancers, with a poor prognosis and resistance to standard treatments. In the last few years, many solid tumor treatments have been revolutionized with the help of immunotherapy. However, this type of treatment has failed to improve the results in glioblastoma patients. Effective immunotherapeutic strategies may be developed after understanding how glioblastoma achieves tumor-mediated immune suppression in both local and systemic landscapes. Biomarkers may help identify patients most likely to benefit from this type of treatment. In this review, we discuss the use of immunotherapy in glioblastoma, with an emphasis on immune checkpoint inhibitors and the factors that influence clinical response. A Pubmed data search was performed for all existing information regarding immune checkpoint inhibitors used for the treatment of glioblastoma. All data evaluating the ongoing clinical trials involving the use of ICIs either as monotherapy or in combination with other drugs was compiled and analyzed.
胶质母细胞瘤是已知的最具侵袭性和致命性的人类癌症之一，预后不良，对标准治疗有抵抗力。在过去的几年中，免疫疗法的帮助下，许多实体瘤的治疗方法发生了革命性的变化。然而，这种治疗方法未能改善胶质母细胞瘤患者的结果。在了解胶质母细胞瘤如何在局部和全身范围内实现肿瘤介导的免疫抑制后，可能会开发出有效的免疫治疗策略。生物标志物可能有助于确定最有可能从这种治疗中受益的患者。在这篇综述中，我们讨论了免疫疗法在胶质母细胞瘤中的应用，重点介绍了免疫检查点抑制剂以及影响临床反应的因素。对所有关于用于治疗胶质母细胞瘤的免疫检查点抑制剂的现有信息进行了 Pubmed 数据检索。编译和分析了评估正在进行的临床试验中单独使用 ICI 或与其他药物联合使用的所有数据。
